A combined therapy with 5-aminosalicylic (5-ASA) tablets (1.6gr/day) and 5-ASA enemas (4gr/twice weekly) was evaluated for maintaining remission of ulcerative colitis in 40 patients. All patients were in complete remission which had been maintained for at least 1 month. The remission was assessed by clinical, endoscopic and histological criteria. Clinical and endoscopical evaluations were performed at intervals of 2 and 6 months, respectively. The relapse-rate associated with this combined therapy was 7.5% at 6 months and 16% at 12 months. In comparison with previous investigations using continuous sulphasalazine, our study showed that the combination of 5-aminosalicylic tablets and enemas provided low relapse rates both at 6 and 12 months, suggesting a potential effectiveness in this form of treatment. Further studies are needed to confirm this result with controlled clinical trials.